SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Aravax Announces Positive Results of Phase 2 Clinical Trial of PVX108, a Novel Immunotherapy for the Treatment of Peanut Allergy

Primary endpoint achieved: PVX108 therapy increased the maximum tolerated dose of peanut compared to

Related stories